CorrectQuestion: Which of the following best describes the mechanism of action of monoclonal antibodies used in targeted cancer therapy? - Aurero

Understanding the Context

In recent years, monoclonal antibodies (mAbs) have revolutionized cancer treatment by offering highly targeted, precision-based therapies. But with growing interest in this cutting-edge field, a common question arises: Which of the following best describes the mechanism of action of monoclonal antibodies used in targeted cancer therapy? Understanding this mechanism is key to appreciating how these therapies selectively attack cancer cells while minimizing damage to healthy tissues.

What Are Monoclonal Antibodies?

Monoclonal antibodies are laboratory-engineered proteins designed to mimic the immune system’s ability to recognize and bind to specific antigens. In oncology, they are designed to target unique proteins (antigens) expressed on the surface of cancer cells, allowing for enhanced specificity and precision in treatment.

Key Insights

Core Mechanisms of Action in Cancer Therapy

Monoclonal antibodies exert their anti-cancer effects through several distinct mechanisms, each tailored to disrupt cancer cell survival, growth, or immune evasion. Key mechanisms include:

1. Direct Targeting of Oncogenic Receptors

Many monoclonal antibodies bind directly to receptor tyrosine kinases (RTKs) overexpressed on cancer cells, such as HER2 in breast cancer (e.g., trastuzumab) or EGFR in lung and colorectal cancers. By blocking these receptors, mAbs prevent activation of signaling pathways that drive uncontrolled cell proliferation—a fundamental step in cancer development.

2. Antibody-Dependent Cellular Cytotoxicity (ADCC)

A major mechanism involves recruiting the body’s own immune system. Once the mAb binds to a tumor antigen, immune cells like natural killer (NK) cells recognize the antibody’s binding site via Fc receptors. This triggers NK cell-mediated destruction of the cancer cell through ADCC, effectively killing the targeted cell without direct engagement.

Final Thoughts

3. Complement-Dependent Cytotoxicity (CDC)

Some monoclonal antibodies activate the complement system, a cascade of proteins that forms pores in target cell membranes, leading to cell lysis. This pathway enhances tumor cell killing through innate immune mechanisms, particularly effective when the antibody binds in a way that allows complement protein assembly.

4. Delivery of Cytotoxic Payloads (Antibody-Drug Conjugates, ADCs)

Advanced mAbs are conjugated to potent chemotherapeutic drugs, radiometals, or toxins. Once internalized by cancer cells, these conjugates release their payload directly inside the malignancy, minimizing systemic toxicity and maximizing intracellular drug concentration. Examples include ado-trastuzumab emtansine (Kadcyla), which delivers a cytotoxic agent via HER2 binding.

5. Immune Checkpoint Modulation

A transformative class of monoclonal antibodies targets immune checkpoints—molecules that cancer cells exploit to evade immune detection. Agents like pembrolizumab (Keytruda) and nivolumab (Opdivo) block PD-1 or PD-L1, restoring T-cell activation and enabling immune-mediated tumor destruction.

6. Induction of Apoptosis and Cell Cycle Arrest

By binding specific surface antigens, monoclonal antibodies can initiate intracellular signaling cascades leading to apoptosis (programmed cell death) or halt cell cycle progression, effectively stopping tumor proliferation.

Why This Mechanism Matters